GNOM - Global X Genomics & Biotechnology ETF
| Assets | $205.68M |
| NAV | $21.76 |
| Expense Ratio | 0.50% |
| PE Ratio | -460.63 |
| Beta (5Y) | 1.10 |
| Dividend (ttm) | $0.03 |
| Dividend Yield | 0.15% |
| Ex-Dividend Date | Dec 30, 2020 |
| 1-Year Return | - |
| Trading Day | April 21 |
| Last Price | $22.36 |
| Previous Close | $21.76 |
| Change ($) | 0.60 |
| Change (%) | 2.76% |
| Day's Open | 21.77 |
| Day's Range | 21.60 - 22.36 |
| Day's Volume | 86,499 |
| 52-Week Range | 13.84 - 28.45 |
Fund Description
The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index (underlying index). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
| Asset Class Equity | Inception Date Apr 5, 2019 |
| Exchange NASDAQ | Ticker Symbol GNOM |
| Index Tracked Solactive Genomics Index | |
Top 10 Holdings
43.10% of assets| Name | Symbol | Weight |
|---|---|---|
| Pacific Biosciences of California | PACB | 5.43% |
| Natera | NTRA | 5.33% |
| Agilent Technologies | A | 4.45% |
| CRISPR Therapeutics | CRSP | 4.39% |
| Illumina | ILMN | 4.39% |
| Arrowhead Pharmaceuticals | ARWR | 3.91% |
| CareDx | CDNA | 3.90% |
| Intellia Therapeutics | NTLA | 3.81% |
| Ultragenyx Pharmaceutical | RARE | 3.77% |
| Alnylam Pharmaceuticals | ALNY | 3.72% |
Genomics could be the next big thing in the biotechnology space. Similarly, the Global X Genomics & Biotechnology ETF (GNOM) could be the next big fund, and is already up 10% to start the new year.
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
It's one thing to discuss the economics of investing in the biotech sector, but it's another to discuss genomics. The sub-sector of the biotech industry has seen strong growth as evidenced by the over 6...
Genomics ETFs have surged of late; here's why
Last week was cheery for Wall Street, with the S&P 500 and Nasdaq recording their best weekly advancement since July.
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
The recent market rout led by the tech selloff has provided investors a great opportunity to tap the stocks under $20.
Jay Jacobs: These High-Growth ETF Themes Have Seen Triple-Digit Returns In Coronavirus Rally
Jay Jacobs, SVP and head of research and strategy at Global X ETFs, joined the podcast this week to discuss thematic investing and the new Global X Telehealth ETF (EDOC). Plus, we take a look at two ETF...
Disruptive technology is always an interesting play for investors to consider and the genomics market is one to watch closely. According to the “Genomics Market – Growth, Trends, and Forecasts (2020-202...
Biotechnology sector-related exchange traded funds were among the leaders on Monday after Invitae Corp. (NYSE: NVTA) announced a $1.4 billion deal for ArcherDX, potentially bolstering the genetic inform...
In the scramble to develop a Coronavirus vaccine, genomics investments are receiving renewed attention and rewarding investors in the process. Those sentiments are applicable to the Global X Genomics & ...
Let us dig into some of the ETFs that are below $20 and are from the hottest areas currently. These low-priced ETFs could lead to huge gains in the coming months.
The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are deliver...
The ETF GNOM hit a 52-week high on May 22. Can it rally further?
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
Declining costs are viewed as one of the biggest factors driving the genomics and data suggest those costs continue falling, a scenario that could benefit ETFs, such as the Global X Genomics & Biotechno...
Due in large part to the J.P. Morgan Health Care conference in San Francisco, the biotechnology industry’s marquee yearly confab, January is often a strong month for related equities and ETFs.
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
When it comes to growth stocks, investors often expect they will pay up to access that.
The Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted earlier this year, making it one of the newest additions to the biotech ETFs fray, but despite its rookie status, GNOM is a fund with amp...